Editorial
doi: 10.2217/fmb.09.101.
Developing an asymptomatic mucosal herpes vaccine: the present and the future
- PMID: 20020824
- PMCID: PMC4512283
- DOI: 10.2217/fmb.09.101
Item in Clipboard
Editorial
Developing an asymptomatic mucosal herpes vaccine: the present and the future
Future Microbiol.
2010 Jan.
No abstract available
Similar articles
-
The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.Vaccine. 2014 Nov 28;32(50):6733-45. doi: 10.1016/j.vaccine.2014.10.002. Epub 2014 Oct 16. Vaccine. 2014. PMID: 25446827 Free PMC article. Review.
-
Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design.Front Immunol. 2019 Mar 6;10:373. doi: 10.3389/fimmu.2019.00373. eCollection 2019. Front Immunol. 2019. PMID: 30894859 Free PMC article. Review.
-
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown.Clin Dev Immunol. 2012;2012:187585. doi: 10.1155/2012/187585. Epub 2012 Mar 26. Clin Dev Immunol. 2012. PMID: 22548113 Free PMC article. Review.
-
Recent advances in vaccine development for herpes simplex virus types I and II.Hum Vaccin Immunother. 2013 Apr;9(4):729-35. doi: 10.4161/hv.23289. Epub 2013 Feb 26. Hum Vaccin Immunother. 2013. PMID: 23442925 Free PMC article. Review.
-
Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection.Vaccine. 2016 Apr 27;34(19):2216-24. doi: 10.1016/j.vaccine.2016.03.022. Epub 2016 Mar 19. Vaccine. 2016. PMID: 27002499
Cited by
-
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.Future Virol. 2012 Apr 1;7(4):371-378. doi: 10.2217/fvl.12.22. Future Virol. 2012. PMID: 22701511 Free PMC article.
-
Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease.Ocul Immunol Inflamm. 2016 Jun;24(3):327-47. doi: 10.3109/09273948.2014.986581. Epub 2014 Dec 23. Ocul Immunol Inflamm. 2016. PMID: 25535823 Free PMC article. Review.
-
A Herpes Simplex Virus Type 1 Human Asymptomatic CD8+ T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a "Humanized" HLA Transgenic Rabbit Model.Invest Ophthalmol Vis Sci. 2015 Jun;56(6):4013-28. doi: 10.1167/iovs.15-17074. Invest Ophthalmol Vis Sci. 2015. PMID: 26098469 Free PMC article.
-
Involvement of STAT4 in IgG subtype switching and ocular HSV-1 replication in mice.Mol Vis. 2010 Jan 26;16:98-104. Mol Vis. 2010. PMID: 20104254 Free PMC article.
-
Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107+ CD8+ T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect against Ocular Herpes Challenge.J Virol. 2018 Jul 31;92(16):e00535-18. doi: 10.1128/JVI.00535-18. Print 2018 Aug 15. J Virol. 2018. PMID: 29899087 Free PMC article.
References
-
- Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L. New concepts in herpes simplex virus vaccine development: notes and challenges from the battlefield. Expert Rev. Vaccines. 2009;8(8):426–437. ■■ Update of the most recent herpes simplex virus subunit vaccine development. - PMC - PubMed
-
- Divito S, Cherpes TL, Hendricks RL. A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol. Res. 2006;36(1–3):119–126. - PubMed
-
- BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 2002;32(8):2274–2281. - PubMed
-
- BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines – yesterday, today, and tomorrow. Lancet Infect. Dis. 2002;2(7):425–431. ■ Describes the new concept of lipopeptide vaccine development. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
